Jupiter Medical Center

Running trials

• Recruiting

  Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  NCT07321652· Phase 3· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Recruiting

  Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  NCT06632977· Phase 2· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· Phase 3· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· Source

• Recruiting

  Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  NCT05561387· Phase 3· Source

• Recruiting

  Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  NCT05673148· Phase 2· Source

• Recruiting

  Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  NCT05929768· Phase 3· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· Source

• Recruiting

  mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  NCT05677490· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Source

• Active, not recruiting

  Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· Phase 3· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· Source

• Active, not recruiting

  Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

  NCT05053152· Phase 2· Source

• Active, not recruiting

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· Phase 3· Source

• Active, not recruiting

  Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

  NCT04340141· Phase 3· Source

• Active, not recruiting

  Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

  NCT04214262· Phase 3· Source

• Active, not recruiting

  De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

  NCT03952585· Phase 2/3· Source

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Source

• Recruiting

  Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  NCT03739814· Phase 2· Source

• Active, not recruiting

  Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

  NCT03660826· Phase 2· Source

• Recruiting

  Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  NCT02734537· Phase 2· Source

• Active, not recruiting

  Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872· Phase 3· Source

• Active, not recruiting

  Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

  NCT01522976· Phase 2· Source

• Active, not recruiting

  Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588· Phase 3· Source

• Active, not recruiting

  Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338· Phase 3· Source

• Active, not recruiting

  Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337· Phase 3· Source

• Active, not recruiting

  Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

  NCT00843882· Phase 3· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Gastric and esophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· Source

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· Source